- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
CORAL GABLES, FL / ACCESSWIRE / February 26, 2019 / The healthcare stock market is one of the few markets which exists in a unique space of opportunity because its encompassing industry is built upon the needs of people, rather than on products that could be considered extraneous. Every person on this planet wants to be healthy, and it is the responsibility of the healthcare sector to meet the growing challenges presented by infectious diseases and ailments which, if unchecked, could disrupt humanity's existence. We look medical experts and healthcare professionals to assist us in feeling better when we're sick, and new advancements in drug treatment, holistic medicines, and the use of medicinal cannabis all indicate a very strong future for the healthcare industry. If these trends remain constant, investors in search of lucrative opportunities could benefit from tapping into healthcare. Premier Health Group (PHGRF) (PHGI), Heat Biologics Inc (HTBX), Zynerba Pharmaceuticals Inc (ZYNE), and Aurora Cannabis Inc (ACB) represent 4 healthcare stocks to keep on your radar this week.
Premier Health Group (PHGRF) (PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers.
Premier Health Group (PHGRF) (PHGI) today announced plans to expand its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care. The Company recently hired four new full-time employees, three Web Software Developers and one User Interface/User Experience (UI/UX) Designer, to support the build-out of its patient-centric platform and mobile app - a beta version of which will be available by end of Q2.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (PHGRF) (PHGI), commented, "the future of healthcare is digitally driven and this strategic investment in growing Cloud Practice's team will enable us to fast-track the build out our app - a much-needed technology innovation in healthcare. Our goal is to tackle the accessibility bottlenecks by putting the power in the hands of patients. Not only will our app enable patients' access to their health care providers, but also allow for cohesive patient care by coordinating and connecting all members of their health care team."
Heat Biologics Inc (HTBX), a biopharmaceutical company developing therapies to help a patient's immune system fight cancer, announced in mid January it had dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).
Following the announcement, Jeff Wolf, Heat's CEO, said, "the expansion of this trial to include a combination of HS-110 with KEYTRUDA® is in line with our strategy to combine our T-cell activation platform with multiple checkpoint inhibitors. We are very excited to begin dosing patients in this cohort."
Zynerba Pharmaceuticals Inc (ZYNE), a leader in innovative pharmaceutically-sourced cannabinoid therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled "Treatment of Fragile X Syndrome with Cannabidiol" which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol.
Per the details of the announcement, this new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company's cannabidiol (CBD) product candidate, ZYN002 Transdermal CBD gel.
Aurora Cannabis Inc (ACB) found itself in headlines today when the Company announced it has agreed to terms to acquire a 51% ownership interest in Gaia Pharm Lda., a license applicant in Portugal, to establish a local facility to produce medical cannabis and derivative products. The company will be renamed "Aurora Portugal Lda". On February 21, 2019, Gaia Pharm Lda. received approval of its application to construct an EU GMP compliant cannabis cultivation facility from INFARMED, a division of the Portuguese Health Ministry, which is responsible for the evaluation, authorization, regulation and control of human medicines as well as health products for the protection of public health.
Terry Booth, CEO of Aurora, commented, "we are very pleased to be entering yet another European market and look forward to collaborating with our joint venture partners, the government of Portugal and the Portuguese medical community, to encourage the development of a rigorously regulated and safe medical cannabis system that is well supplied and accessible to patients."
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: